Neurocrine Biosciences (NASDAQ:NBIX) Director Sells 7,200 Shares of Company Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director George Morrow sold 7,200 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $166.37, for a total value of $1,197,864.00. Following the completion of the sale, the director owned 10,386 shares of the company’s stock, valued at approximately $1,727,918.82. The trade was a 40.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Neurocrine Biosciences Price Performance

Shares of Neurocrine Biosciences stock traded up $19.50 during trading on Tuesday, reaching $164.85. 4,056,875 shares of the company traded hands, compared to its average volume of 1,234,742. The company has a 50 day moving average price of $146.49 and a 200-day moving average price of $147.45. Neurocrine Biosciences, Inc. has a 1-year low of $122.14 and a 1-year high of $186.12. The firm has a market capitalization of $16.76 billion, a PE ratio of 24.17, a P/E/G ratio of 0.64 and a beta of 0.36.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Monday, November 2nd. The company reported $3.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $1.38. The company had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.04 billion. Neurocrine Biosciences had a net margin of 20.91% and a return on equity of 22.43%. The business’s revenue was up 41.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.04 EPS. Equities research analysts expect that Neurocrine Biosciences, Inc. will post 7.72 earnings per share for the current year.

Hedge Funds Weigh In On Neurocrine Biosciences

A number of hedge funds have recently bought and sold shares of NBIX. BlackRock Inc. purchased a new stake in shares of Neurocrine Biosciences in the second quarter valued at about $2,310,886,000. Renaissance Technologies LLC lifted its position in shares of Neurocrine Biosciences by 8.0% during the first quarter. Renaissance Technologies LLC now owns 2,418,897 shares of the company’s stock valued at $318,665,000 after purchasing an additional 180,100 shares in the last quarter. First Trust Advisors LP lifted its position in shares of Neurocrine Biosciences by 97.0% during the first quarter. First Trust Advisors LP now owns 959,217 shares of the company’s stock valued at $126,367,000 after purchasing an additional 472,408 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in Neurocrine Biosciences during the second quarter worth about $117,827,000. Finally, Ieq Capital LLC purchased a new position in Neurocrine Biosciences during the second quarter worth about $107,914,000. 92.59% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Quarterly results topped expectations. Revenue increased 41% year over year to $1.12 billion, and earnings were $3.29 per share. Product sales exceeded $1 billion for the first time, with strong demand across the portfolio. Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: INGREZZA guidance was raised. Neurocrine now expects 2026 net sales of $2.9 billion to $2.925 billion, reflecting continued demand for its leading product. The company also cited growth from Crenessity. NBIX Beats on Q3 Earnings & Sales, Raises ’26 Ingrezza Sales View
• Positive Sentiment: Several analysts lifted price targets. Canaccord raised its target to $220 and kept a Buy rating; Piper Sandler raised its target to $215 with an Overweight rating, and RBC raised its target to $190 with an Outperform rating. Canaccord Genuity Group recommendations
• Neutral Sentiment: Neurocrine announced a Phase 2 Alzheimer’s study and plans to present its scientific and neuropsychiatry pipeline at the NEI Fall Congress. These developments may support longer-term pipeline visibility, but no study results were reported. Neurocrine Starts Phase 2 Alzheimer’s Study
• Neutral Sentiment: Morgan Stanley raised its price target to $185 but maintained an Equal Weight rating, signaling a more cautious view than the other target increases. Morgan Stanley recommendations

Analyst Ratings Changes

A number of research analysts have recently issued reports on NBIX shares. Canaccord Genuity Group lifted their price objective on shares of Neurocrine Biosciences from $210.00 to $220.00 and gave the company a “buy” rating in a report on Tuesday. Guggenheim began coverage on shares of Neurocrine Biosciences in a report on Tuesday, October 6th. They issued a “buy” rating and a $207.00 target price on the stock. Morgan Stanley raised their price target on shares of Neurocrine Biosciences from $183.00 to $185.00 and gave the company an “equal weight” rating in a research report on Tuesday. Wall Street Zen downgraded Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research note on Sunday, August 9th. Finally, TD Cowen boosted their price objective on Neurocrine Biosciences from $200.00 to $220.00 and gave the stock a “buy” rating in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $201.55.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.